Janney Montgomery Scott Upgrades Clovis Oncology (CLVS) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
Clovis Oncology (CLVS) PT Raised to $111 at JPMorgan
June 20, 2017 8:07 AM EDTJPMorgan analyst Cory Kasimov raised his price target on Clovis Oncology (NASDAQ: CLVS) to $111.00 (from $72.00) while maintaining a Overweight rating.
Kasimov said the ARIEL 3 topline data represents more or less a best case scenario for CLVS. He thinks ARIEL 3... More
Clovis Oncology (CLVS) PT Raised to $107 at Credit Suisse; Major De-Risking Event
June 20, 2017 6:59 AM EDTCredit Suisse raised its price target on Clovis Oncology (NASDAQ: CLVS) to $107.00 (from $88.00) while maintaining an Outperform rating on increased probability of success in 1L and 2L ovarian after ARIEL3 success
Alethia Young viewed the data today as a major de-risking... More
Clovis Oncology (CLVS) PT Raised to $90 at Goldman Sachs, Raises Estimates, Possible Takeout Candidate
June 20, 2017 6:32 AM EDTGoldman Sachs raised its price target on Clovis Oncology (NASDAQ: CLVS) to $90.00 (from $67.00) while maintaining a Neutral rating.
Analyst Dr. Terrence Flynn updates Rubraca estimates and now models Rubraca WW peak sales of $1.8 billion compared with the prior estimate of $1.2... More
Clovis Oncology (CLVS) PT Raised to $114 at Leerink Partners, Prime takeout Candidate
June 19, 2017 2:49 PM EDTLeerink Partners raised its price target on Clovis Oncology (NASDAQ: CLVS) to $114.00 (from $85.00) while maintaining a Outperform rating.
Te analyst says the new price target is reflective of three key points:
our previously outlined best-case scenario for Rubraca,incorporation of a low... More